NAS:KALV (USA) Also trade in: Germany

KalVista Pharmaceuticals Inc

$ 19.9 0.15 (0.76%)
Volume: 140,735 Avg Vol (1m): 176,957
Market Cap $: 343.22 Mil Enterprise Value $: 232.18 Mil
P/E (TTM): 0.00 P/B: 3.35
Earnings Power Value -688.03
Net Current Asset Value 5.89
Tangible Book 6.04
Projected FCF -3.38
Median P/S Value 30.23
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1019.70
Cash-To-Debt ranked higher than
52.60% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
KALV: 1019.7
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.32, Med: 76.23, Max: 10000
Current: 1019.7
0.32
10000
Equity-to-Asset 0.82
Equity-to-Asset ranked lower than
75.75% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
KALV: 0.82
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -6.65, Med: 0.87, Max: 0.95
Current: 0.82
-6.65
0.95
Debt-to-EBITDA -0.01
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
KALV: -0.01
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.53, Med: -0.56, Max: -0.01
Current: -0.01
-1.53
-0.01
Interest Coverage No Debt
Interest Coverage ranked lower than
64.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
KALV: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.82
DISTRESS
GREY
SAFE
Beneish M-Score 1.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 13.32%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -119.35
Operating Margin ranked lower than
57.95% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
KALV: -119.35
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -40265.52, Med: -711.72, Max: -119.18
Current: -119.35
-40265.52
-119.18
Net Margin % -71.77
Net Margin ranked lower than
55.30% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
KALV: -71.77
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -46065.52, Med: -536.15, Max: -71.77
Current: -71.77
-46065.52
-71.77
ROE % -22.09
ROE ranked lower than
56.83% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
KALV: -22.09
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -53.96, Med: -53.96, Max: -22.09
Current: -22.09
-53.96
-22.09
ROA % -14.56
ROA ranked higher than
50.09% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
KALV: -14.56
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -217.52, Med: -62.96, Max: -14.56
Current: -14.56
-217.52
-14.56
ROC (Joel Greenblatt) % -1136.20
ROC (Joel Greenblatt) ranked lower than
70.27% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
KALV: -1136.2
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -41029.73, Med: -8987.78, Max: -1136.2
Current: -1136.2
-41029.73
-1136.2
3-Year Total Revenue Growth Rate 66.90
3-Year Revenue Growth Rate ranked lower than
83.41% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
KALV: -50.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -50.9, Med: 66.35, Max: 128.9
Current: -50.9
-50.9
128.9
3-Year Total EBITDA Growth Rate -32.00
3-Year EBITDA Growth Rate ranked higher than
95.89% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
KALV: 61.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -132.8, Med: -13.85, Max: 61.2
Current: 61.2
-132.8
61.2
3-Year EPS w/o NRI Growth Rate 64.80
3-Year EPS w/o NRI Growth Rate ranked higher than
95.15% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
KALV: 64.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -131, Med: 0.2, Max: 64.8
Current: 64.8
-131
64.8

» KALV's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:KALV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2834
Compare TPE:1733 XPAR:GNRO OTCPK:NWBO OSL:TRVX NAS:OPHT OSTO:MVIR B ASX:MDC TSX:APS NAS:LPTX NAS:KRYS NAS:EIGR XMCE:ORY OTCPK:CYDY FRA:PB9 NAS:BLRX ROCO:4193 TSE:4572 LSE:DDDD ROCO:4726 OSTO:IBT B
Traded in other countries 4XC1.Germany
Address 55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates through the region of United States.

Ratios

Current vs industry vs history
PB Ratio 3.35
PB Ratio ranked lower than
55.41% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
KALV: 3.35
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.29, Med: 3.01, Max: 9.1
Current: 3.35
0.29
9.1
PS Ratio 14.31
PS Ratio ranked lower than
56.75% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
KALV: 14.31
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.68, Med: 21.78, Max: 8213.33
Current: 14.31
3.68
8213.33
EV-to-EBIT -10.76
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
KALV: -10.76
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -19.2, Med: -2.3, Max: 1.8
Current: -10.76
-19.2
1.8
EV-to-EBITDA -10.93
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
KALV: -10.93
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -19.5, Med: -2.3, Max: 1.8
Current: -10.93
-19.5
1.8
EV-to-Revenue 12.85
EV-to-Revenue ranked higher than
52.40% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
KALV: 12.85
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -1587.8, Med: 15.3, Max: 6283
Current: 12.85
-1587.8
6283
Current Ratio 6.59
Current Ratio ranked lower than
68.16% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
KALV: 6.59
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.39, Med: 7.59, Max: 19.68
Current: 6.59
0.39
19.68
Quick Ratio 6.59
Quick Ratio ranked lower than
64.90% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
KALV: 6.59
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.39, Med: 7.59, Max: 19.68
Current: 6.59
0.39
19.68

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -84.10
3-Year Share Buyback Rate ranked lower than
92.30% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
KALV: -84.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -107.4, Med: -60.75, Max: -33.6
Current: -84.1
-107.4
-33.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.29
Price-to-Tangible-Book ranked higher than
52.80% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
KALV: 3.29
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.36, Med: 2.63, Max: 4.42
Current: 3.29
0.36
4.42
Price-to-Median-PS-Value 0.66
Price-to-Median-PS-Value ranked higher than
73.30% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
KALV: 0.66
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 1.06, Max: 303.33
Current: 0.66
0.18
303.33
Earnings Yield (Joel Greenblatt) % -9.31
Earnings Yield (Greenblatt) ranked lower than
67.90% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
KALV: -9.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -407.8, Med: -37.7, Max: 3981.3
Current: -9.31
-407.8
3981.3

More Statistics

Revenue (TTM) (Mil) $ 18.04
EPS (TTM) $ -0.98
Beta 1.75
Volatility % 101.39
52-Week Range $ 7.73 - 34.92
Shares Outstanding (Mil) 17.25

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y